Wall Street Zen Upgrades LENSAR (NASDAQ:LNSR) to Hold

LENSAR (NASDAQ:LNSR) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

LNSR has been the topic of several other reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of LENSAR in a research report on Friday, August 7th. BTIG Research upped their price target on LENSAR from $7.00 to $9.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Lake Street Capital restated a “buy” rating and issued a $13.00 price objective on shares of LENSAR in a report on Thursday. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $11.00.

LENSAR Price Performance

Shares of NASDAQ:LNSR opened at $8.20 on Friday. The company has a market capitalization of $100.70 million, a P/E ratio of -24.85 and a beta of 0.89. LENSAR has a 52-week low of $4.95 and a 52-week high of $12.96. The stock’s fifty day simple moving average is $5.89 and its 200-day simple moving average is $7.34.

LENSAR (NASDAQ:LNSR) last released its earnings results on Thursday, August 13th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.16) by $0.26. The firm had revenue of $16.50 million during the quarter, compared to analysts’ expectations of $14.65 million. LENSAR had a net margin of 57.57% and a negative return on equity of 529.08%.

Hedge Funds Weigh In On LENSAR

Several institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets grew its position in shares of LENSAR by 129.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,008 shares of the company’s stock worth $25,000 after acquiring an additional 1,131 shares in the last quarter. Bank of New York Mellon Corp bought a new position in LENSAR during the second quarter worth $58,000. JPMorgan Chase & Co. lifted its stake in LENSAR by 584.3% during the second quarter. JPMorgan Chase & Co. now owns 4,674 shares of the company’s stock worth $62,000 after purchasing an additional 3,991 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in LENSAR in the second quarter worth $68,000. Finally, Sanctuary Advisors LLC acquired a new position in LENSAR in the second quarter worth $96,000. 40.15% of the stock is currently owned by hedge funds and other institutional investors.

Key LENSAR News

Here are the key news stories impacting LENSAR this week:

• Positive Sentiment: LENSAR reported second-quarter revenue of $16.5 million, above analysts’ $14.65 million consensus estimate, and earnings of $0.10 per share versus expectations for a $0.16 loss. The results point to a significant improvement in profitability and operating performance. LENSAR Reports Second Quarter 2026 Results and Provides Business Update
• Positive Sentiment: The company placed 10 ALLY Robotic Cataract Laser Systems during the quarter, increasing its installed base to 445 systems. The ALLY backlog stood at 13 systems at June 30, suggesting continued near-term demand and potential future revenue. LENSAR signals opex to rise modestly as ALLY backlog reaches 13 systems
• Positive Sentiment: Recurring revenue reached $13.7 million, while ALLY placements grew 30%. The recurring-revenue base could improve visibility and support more consistent results as the installed system base expands. LENSAR Q2 2026 Earnings Call Highlights
• Positive Sentiment: BTIG Research raised its LENSAR price target from $7 to $9 and assigned a Buy rating, reflecting greater confidence following the earnings beat and business update.
• Neutral Sentiment: Management indicated that operating expenses will increase modestly, likely reflecting investments needed to support commercialization and the growing ALLY system base. This could temper the pace of future margin expansion.

LENSAR Company Profile

LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment.